Key statistics
On Friday, Ultragenyx Pharmaceutical Inc (0LIF:LSE) closed at 50.52, -15.52% below its 52-week high of 59.80, set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 50.52 |
Low | 50.52 |
Bid | -- |
Offer | -- |
Previous close | 50.48 |
Average volume | 418.88 |
---|---|
Shares outstanding | 92.34m |
Free float | 89.00m |
P/E (TTM) | -- |
Market cap | 4.65bn USD |
EPS (TTM) | -6.46 USD |
Data delayed at least 20 minutes, as of Nov 08 2024 17:10 GMT.
More ▼
Announcements
- Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
- Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
- Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
- Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
- Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
- Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)
- Ultragenyx to Participate in Investor Conferences in September
- Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
More ▼